| 1 |
34958867 | Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells. | 2022 Mar |
2 |
| 2 |
35091441 | Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. | 2022 Apr 1 |
1 |
| 3 |
35163586 | Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. | 2022 Jan 31 |
1 |
| 4 |
35607887 | Talazoparib in BRCA-mutated advanced breast cancer: is earlier better? | 2022 Jun |
1 |
| 5 |
33710534 | An Overview of PARP Inhibitors for the Treatment of Breast Cancer. | 2021 May |
1 |
| 6 |
34231369 | Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer. | 2021 Sep |
2 |
| 7 |
34309473 | Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. | 2021 Oct |
1 |
| 8 |
31823331 | Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. | 2020 Feb |
1 |
| 9 |
32158196 | Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. | 2020 |
2 |
| 10 |
32162822 | Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. | 2020 Mar |
3 |
| 11 |
32195033 | Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. | 2020 |
1 |
| 12 |
32215876 | Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. | 2020 Jun |
1 |
| 13 |
32243226 | Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. | 2020 Jun 20 |
1 |
| 14 |
32276934 | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. | 2020 Jul |
1 |
| 15 |
32337496 | Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. | 2020 Feb |
1 |
| 16 |
32468579 | Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. | 2020 Oct |
1 |
| 17 |
32468645 | Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. | 2020 Oct |
1 |
| 18 |
32471249 | PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? | 2020 May 27 |
1 |
| 19 |
32717529 | The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction. | 2020 Oct 1 |
1 |
| 20 |
32816949 | A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. | 2020 Oct 15 |
1 |
| 21 |
32828825 | Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. | 2020 Nov |
1 |
| 22 |
32869930 | Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. | 2020 Nov |
1 |
| 23 |
32881420 | Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. | 2020 Dec |
1 |
| 24 |
33257598 | Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis. | 2020 Nov 30 |
3 |
| 25 |
33490218 | Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis? | 2020 Dec |
1 |
| 26 |
30563931 | A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). | 2019 May 1 |
4 |
| 27 |
30789866 | Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. | 2019 May |
1 |
| 28 |
30806045 | Major clinical research advances in gynecologic cancer in 2018. | 2019 Mar |
1 |
| 29 |
30912451 | Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. | 2019 May |
1 |
| 30 |
31099663 | Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. | 2019 Jan |
1 |
| 31 |
31303769 | Evidence to date: talazoparib in the treatment of breast cancer. | 2019 |
1 |
| 32 |
31347614 | Talazoparib to treat BRCA-positive breast cancer. | 2019 Jul |
3 |
| 33 |
29189915 | Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. | 2018 Feb |
1 |
| 34 |
29242215 | Talazoparib Bests Chemo for Breast Cancer. | 2018 Feb |
1 |
| 35 |
29660759 | PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. | 2018 Jun 15 |
1 |
| 36 |
30061215 | Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer. | 2018 Aug |
1 |
| 37 |
30110579 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. | 2018 Aug 23 |
2 |
| 38 |
30124753 | Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. | 2018 Sep 1 |
1 |
| 39 |
30146245 | Talazoparib for BRCA-mutated advanced breast cancer. | 2018 Oct |
1 |
| 40 |
30181424 | Resurrection of PARP Inhibitors in Breast Cancer. | 2018 Sep |
1 |
| 41 |
30255456 | Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. | 2018 Sep 25 |
1 |
| 42 |
30359909 | Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. | 2018 Nov |
1 |
| 43 |
30506138 | Talazoparib: First Global Approval. | 2018 Dec |
1 |
| 44 |
30518089 | Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. | 2018 Dec 4 |
2 |
| 45 |
28242752 | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. | 2017 Jun |
2 |
| 46 |
29238749 | A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. | 2017 |
3 |
| 47 |
27708213 | Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. | 2016 Nov 22 |
1 |